News | Contrast Media | January 19, 2018

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

Focus will be on hospital-based products that could benefit from reduced renal toxicity

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization. The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals, a privately-held Lenexa, Kansas-based medical invention company that Ligand acquired in January 2018 for $2 million in cash plus earnouts.

Ligand CEO John Higgins explained that contrast agents are an important component of the diagnostic imaging market, however they can be toxic and are known to cause kidney damage in some patients. He added that Captisol is a specialized cyclodextrin that plays a role in protecting kidneys from the damaging effects of these agents. Captisol-enabled (CE) iohexol, marketed as Omnipaque by GE Healthcare, has been shown to prevent nephrotoxicity by more than 50 percent in animal models.1

The company said the initial internal program is focused on a CE formulation of iohexol given the large global market, lack of alternatives and focused development path for use in the cardiovascular imaging setting. The initial CE-iohexol program will focus on partnering-enabling studies, with an estimated $6 million of program spend by Ligand over approximately three years.

For more information: www.ligand.com

References

1. Rowe ES, et al. Journal of Neuroimaging 2016; 26(5):511-8

Related Content

News | Cardiac Imaging

November 10, 2021 — Philips, a global leader in health technology, announced that it has signed an agreement to acquire ...

Home November 10, 2021
Home
News | Cardiac Imaging

November 1, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), radiologists need to be cognizant of the ...

Home November 01, 2021
Home
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Home October 06, 2021
Home
News | Cardiac Imaging

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by ...

Home September 22, 2021
Home
Feature | Cardiac Imaging | By Dave Fornell, Editor

In the past several years, a few cardiac ultrasound vendors have developed new ways to image the intricate flow of ...

Home August 17, 2021
Home
News | Cardiac Imaging

June 15, 2021 — A cardiac MRI of athletes who had COVID-19 is seven times more effective in detecting inflammation of ...

Home June 15, 2021
Home
News | Cardiac Imaging

June 14, 2021 — Heart disease and cancer are the leading causes of death in the United States, and it’s increasingly ...

Home June 14, 2021
Home
News | Cardiac Imaging

May 12, 2021 — According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 ...

Home May 12, 2021
Home
News | Cardiac Imaging

March 31, 2021 — ScImage Inc. celebrates its cloud partnership with Digirad Health after a year of successful deployment ...

Home March 31, 2021
Home
News | Cardiac Imaging

November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women ...

Home November 17, 2020
Home
Subscribe Now